Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex has randomized 135 of a planned 182 patients in its Phase 2b trial of Allocetra for moderate-to-severe age-related knee osteoarthritis. The trial is recruiting across sites in the US, Denmark and Poland, with topline six-month data expected by mid-2027. The program holds FDA RMAT designation granted in July 2026. This is an enrollment-progress update, not a data readout; the key binary catalyst remains the mid-2027 topline results.
Key figures
- Drug Name
- Allocetra
- Phase Of Trial
- Phase 2b
- Data readout
- topline six-month data by mid-2027
- Patients planned
- 182
- Patients randomized
- 135
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.